Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice

Pemafibrate (PEM) is a novel lipid-lowering drug classified as a selective peroxisome proliferator-activated receptor α (PPARα) modulator whose binding efficiency to PPARα is superior to that of fibrates. This agent is also useful for non-alcoholic fatty liver disease and primary biliary cholangitis...

Full description

Bibliographic Details
Main Authors: Zhe Zhang, Pan Diao, Xuguang Zhang, Takero Nakajima, Takefumi Kimura, Naoki Tanaka
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Biomedicines
Subjects:
β-oxidation
pemafibrate
PPARα
triglycerides
liver
FGF21
Online Access:https://www.mdpi.com/2227-9059/10/7/1667

Internet

https://www.mdpi.com/2227-9059/10/7/1667

Similar Items